NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 09 10:05AM ET
9.92
Dollar change
+0.14
Percentage change
1.47
%
IndexRUT P/E- EPS (ttm)-2.38 Insider Own17.41% Shs Outstand113.86M Perf Week37.45%
Market Cap1.13B Forward P/E- EPS next Y-2.01 Insider Trans0.22% Shs Float94.03M Perf Month45.94%
Enterprise Value1.01B PEG- EPS next Q-0.59 Inst Own100.09% Short Float17.57% Perf Quarter116.67%
Income-256.98M P/S- EPS this Y9.54% Inst Trans17.37% Short Ratio7.12 Perf Half Y25.93%
Sales0.00M P/B10.19 EPS next Y9.45% ROA-70.93% Short Interest16.52M Perf YTD27.23%
Book/sh0.97 P/C4.60 EPS next 5Y28.42% ROE-84.04% 52W High12.61 -21.30% Perf Year17.58%
Cash/sh2.16 P/FCF- EPS past 3/5Y-9.70% 10.02% ROIC-109.60% 52W Low3.72 166.76% Perf 3Y5.68%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility9.12% 7.59% Perf 5Y427.85%
Dividend TTM- EV/Sales- EPS Y/Y TTM4.02% Oper. Margin- ATR (14)0.64 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.13 Sales Y/Y TTM- Profit Margin- RSI (14)83.28 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio5.13 EPS Q/Q14.72% SMA2029.72% Beta0.29 Target Price18.64
Payout- Debt/Eq0.08 Sales Q/Q- SMA5059.26% Rel Volume11.46 Prev Close9.78
Employees205 LT Debt/Eq0.07 EarningsMay 06 BMO SMA20024.81% Avg Volume2.32M Price9.92
IPOMar 29, 2018 Option/ShortYes / Yes EPS/Sales Surpr.-7.17% - Trades Volume3,594,982 Change1.47%
Date Action Analyst Rating Change Price Target Change
Mar-07-25Initiated Scotiabank Sector Outperform $17
Dec-11-24Downgrade Needham Buy → Hold
Feb-26-24Downgrade Robert W. Baird Outperform → Neutral $14 → $8
Feb-08-24Initiated Citigroup Buy $11
Dec-11-23Downgrade Wedbush Outperform → Neutral $5
Dec-08-23Initiated JP Morgan Overweight $18
Apr-28-23Initiated Robert W. Baird Outperform $20
Mar-27-23Resumed H.C. Wainwright Buy $28
Dec-14-22Initiated Needham Buy $24
Jun-28-22Initiated Guggenheim Buy $15
Jul-08-25 09:36PM
04:26PM
10:54AM
Jul-07-25 07:06AM
Jun-11-25 08:00AM
08:00AM Loading…
May-29-25 08:00AM
May-13-25 09:55AM
08:50AM
May-06-25 08:00AM
May-05-25 07:57AM
Apr-25-25 08:08AM
Apr-20-25 06:16AM
Apr-16-25 10:03AM
Apr-09-25 04:28PM
Mar-25-25 04:31PM
08:32AM Loading…
Mar-20-25 08:32AM
Mar-07-25 08:00AM
Feb-27-25 08:00AM
Feb-25-25 08:00AM
Feb-10-25 09:15AM
Jan-30-25 08:00AM
Jan-13-25 08:00AM
Jan-08-25 08:00AM
Dec-09-24 07:00AM
Dec-08-24 12:00PM
Nov-05-24 09:00AM
Oct-23-24 07:00AM
Oct-09-24 08:03AM
Sep-03-24 08:00AM
Sep-02-24 05:22PM
08:00AM Loading…
Aug-06-24 08:00AM
Jun-28-24 09:18AM
Jun-27-24 08:00AM
Jun-14-24 07:30AM
May-23-24 05:05PM
05:01PM
May-07-24 01:52PM
08:00AM
Apr-09-24 09:00AM
Mar-13-24 07:06AM
Feb-28-24 04:32AM
Feb-26-24 08:00AM
Feb-22-24 02:30PM
Feb-14-24 07:00AM
Feb-05-24 09:00AM
Jan-09-24 08:00AM
Jan-02-24 08:00AM
Dec-11-23 07:55AM
Dec-09-23 01:30PM
Dec-07-23 09:00AM
Dec-04-23 08:00AM
Nov-29-23 08:00AM
Nov-02-23 09:00AM
Oct-14-23 12:30PM
Aug-13-23 08:51AM
Aug-08-23 08:00AM
Jul-10-23 07:35PM
Jun-09-23 04:01PM
Jun-07-23 09:00AM
Jun-06-23 08:25PM
04:05PM
Jun-03-23 02:15PM
May-23-23 08:00AM
May-09-23 08:00AM
Apr-17-23 09:00AM
Apr-12-23 08:00AM
Mar-14-23 08:00AM
Feb-01-23 08:00AM
Jan-11-23 11:03AM
Jan-09-23 08:00AM
Jan-05-23 08:00AM
Dec-11-22 05:30PM
Dec-05-22 08:00AM
Nov-28-22 04:15PM
Nov-14-22 07:00AM
Nov-09-22 08:00AM
Nov-03-22 09:05AM
Oct-26-22 07:00AM
Aug-14-22 12:21PM
Aug-09-22 07:00AM
Aug-04-22 11:22AM
Jun-20-22 11:09AM
Jun-16-22 04:01PM
Jun-13-22 09:48PM
06:00AM
Jun-10-22 07:00AM
Jun-06-22 10:15AM
Jun-02-22 08:00AM
May-12-22 10:00AM
May-10-22 07:00AM
May-06-22 08:00AM
Apr-11-22 07:00AM
Mar-29-22 07:00AM
Mar-15-22 07:00AM
Mar-08-22 05:10PM
Feb-01-22 05:29AM
Jan-05-22 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Nov-02-21 07:00AM
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pinnow ColeChief Commercial OfficerJan 14 '25Buy7.6043,750332,41245,848Jan 15 07:00 AM